RU2000111434A - A method for modulating the function of serine / threonine protein-based compound 5-AZAHINOKSALINA, methods for identifying compounds that modulate the function of serine / threonine protein kinase A method for preventing or treating pathological conditions, the pharmaceutical composition, the compound based on a 5-AZAHINOKSALINA AND METHOD OF SYNTHESIS - Google Patents
A method for modulating the function of serine / threonine protein-based compound 5-AZAHINOKSALINA, methods for identifying compounds that modulate the function of serine / threonine protein kinase A method for preventing or treating pathological conditions, the pharmaceutical composition, the compound based on a 5-AZAHINOKSALINA AND METHOD OF SYNTHESISInfo
- Publication number
- RU2000111434A RU2000111434A RU2000111434/14A RU2000111434A RU2000111434A RU 2000111434 A RU2000111434 A RU 2000111434A RU 2000111434/14 A RU2000111434/14 A RU 2000111434/14A RU 2000111434 A RU2000111434 A RU 2000111434A RU 2000111434 A RU2000111434 A RU 2000111434A
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- independently selected
- membered aryl
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 26
- 230000001575 pathological Effects 0.000 title claims 5
- 230000000051 modifying Effects 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 title 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 title 1
- 239000004473 Threonine Substances 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 101710014951 spkA-1 Proteins 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 230000002194 synthesizing Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 125000005418 aryl aryl group Chemical group 0.000 claims 33
- 125000001072 heteroaryl group Chemical group 0.000 claims 29
- 125000001424 substituent group Chemical group 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical group 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000002148 esters Chemical group 0.000 claims 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 17
- 125000004953 trihalomethyl group Chemical group 0.000 claims 15
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 15
- 101710025088 66 Proteins 0.000 claims 13
- 101700024634 CDK16 Proteins 0.000 claims 13
- 101700036757 ERN1 Proteins 0.000 claims 13
- 102100016655 ERN1 Human genes 0.000 claims 13
- 101700014948 ERN2 Proteins 0.000 claims 13
- 101700085586 IRE1A Proteins 0.000 claims 13
- 101700019719 IRE1B Proteins 0.000 claims 13
- 101710007526 MAP3K14 Proteins 0.000 claims 13
- 101700044505 PUB33 Proteins 0.000 claims 13
- 101700045570 PUB34 Proteins 0.000 claims 13
- 101700046887 PUB35 Proteins 0.000 claims 13
- 101700066160 PUB51 Proteins 0.000 claims 13
- 101700067511 PUB52 Proteins 0.000 claims 13
- 101700068819 PUB53 Proteins 0.000 claims 13
- 101700086326 PUB70 Proteins 0.000 claims 13
- 150000007942 carboxylates Chemical class 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 101700052395 ire-1 Proteins 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 239000003153 chemical reaction reagent Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 6
- 239000000758 substrate Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000001412 amines Chemical class 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- 101700067074 MAPK Proteins 0.000 claims 3
- 101710041325 MAPKAPK2 Proteins 0.000 claims 3
- 150000001299 aldehydes Chemical class 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 150000002576 ketones Chemical class 0.000 claims 3
- 239000000376 reactant Substances 0.000 claims 3
- 101710024887 rl Proteins 0.000 claims 3
- 101700045897 spk-1 Proteins 0.000 claims 3
- 150000003457 sulfones Chemical class 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 239000006166 lysate Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000000771 oncological Effects 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- BVQVLAIMHVDZEL-UHFFFAOYSA-N 1-phenyl-1,2-propanedione Chemical compound CC(=O)C(=O)C1=CC=CC=C1 BVQVLAIMHVDZEL-UHFFFAOYSA-N 0.000 claims 1
- MTMONFVFAYLRSG-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-2-oxoacetaldehyde Chemical compound OC1=CC=C(C(=O)C=O)C=C1 MTMONFVFAYLRSG-UHFFFAOYSA-N 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 claims 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N Benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 239000007868 Raney catalyst Substances 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- 206010048218 Xeroderma Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 201000005216 brain cancer Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000003197 catalytic Effects 0.000 claims 1
- 230000024881 catalytic activity Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000003176 fibrotic Effects 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000002934 lysing Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical group [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 1
- LJDZFAPLPVPTBD-UHFFFAOYSA-M nitroformate Chemical group [O-]C(=O)[N+]([O-])=O LJDZFAPLPVPTBD-UHFFFAOYSA-M 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003638 reducing agent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
Claims (40)
где (а) R1, R2, R3, R4 и R6 независимо выбирают из группы, включающей
(i) водород;
(ii) насыщенный или ненасыщенный алкил, замещенный по выбору пяти- или шестичленным арильным или гетероарильным остатками, в которых кольцо по выбору замещено одним, двумя или тремя заместителями, независимо выбранными из группы, включающей алкил, галоген, тригалогенметил, карбоксилат, нитро и сложноэфирные остатки;
(iii) амин формулы NX2X3, где Х2 и Х3 независимо выбирают из группы, включающей водород, насыщенный или ненасыщенный алкил и пяти- или шестичленные арильные или гетероарильные остатки;
(iv) галоген или тригалогенметил;
(v) кетон формулы -СО-Х4, где Х4 выбирают из группы, включающей водород, алкил и пяти- или шестичленные арильные или гетероарильные остатки;
(vi) карбоновая кислота формулы -(Х5)n-СООН или сложный эфир формулы -(X6)n-COO-X7, где X5, X6 и Х7 независимо выбирают из группы, включающей алкил и пяти- или шестичленные арильные или гетероарильные остатки, а n равно 0 или 1;
(vii) спирт формулы (X8)n-OH или алкоксиостаток формулы -(X8)n-O-Х9, где Х8 и Х9 независимо выбирают из группы, включающей водород, насыщенный или ненасыщенный алкил и пяти- или шестичленные арильные или гетероарильные остатки, в кольце которых по выбору имеется один или более заместителей, которые независимо выбирают из группы, включающей алкил, галоген, тригалогенметил, карбоксилат, нитро и сложноэфирные остатки, а n равно 0 или 1;
(viii) амид формулы -NНСОХ10, где Х10 выбирают из группы, включающей алкил, гидроксил и пяти- или шестичленные арильные или гетероарильные остатки, в кольце которых по выбору имеется один или более заместителей, которые независимо выбирают из группы, включающей алкил, галоген, тригалогенметил, карбокислат, нитро или сложноэфирные остатки;
(ix) -SO2NX11X12, где Х11 и Х12 независимо выбирают из группы, включающей водород, алкил и пяти- или шестичленные арильные или гетероарильные остатки;
(х) пяти- или шестичленный арильный или гетероарильный остаток, по выбору замещенный одним, двумя или тремя заместителями, независимо выбранными из группы, включающей алкил, галоген, тригалогенметил, карбоксилат, нитро и сложноэфирные остатки;
(xi) альдегид формулы -СО-Н и
(xii) сульфон формулы -SO2-X13, где Х13 выбирают из группы, включающей насыщенный или ненасыщенный алкил и пяти- или шестичленные арильные или гетероарильные остатки; и
(б) X1 выбирают из группы, включающей азот, серу и кислород.10. The method according to p. 1, characterized in that the said compound based on 5-azachinoxaline has the structure represented by the formula
where (a) R 1 , R 2 , R 3 , R 4 and R 6 are independently selected from the group consisting of
(i) hydrogen;
(ii) saturated or unsaturated alkyl optionally substituted with five- or six-membered aryl or heteroaryl residues in which the ring is optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, halogen, trihalogenomethyl, carboxylate, nitro and ester residues;
(iii) an amine of the formula NX 2 X 3 , where X 2 and X 3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five- or six-membered aryl or heteroaryl residues;
(iv) halogen or trihalogenomethyl;
(v) a ketone of the formula —CO — X 4 , wherein X 4 is selected from the group consisting of hydrogen, alkyl, and five- or six-membered aryl or heteroaryl residues;
(vi) a carboxylic acid of the formula - (X 5 ) n -COOH or an ester of the formula - (X 6 ) n -COO-X 7 , where X 5 , X 6 and X 7 are independently selected from the group consisting of alkyl and five- or six-membered aryl or heteroaryl residues, and n is 0 or 1;
(vii) an alcohol of the formula (X 8 ) n- OH or an alkoxy radical of the formula - (X 8 ) n -O-X 9 , where X 8 and X 9 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five- or six-membered aryl or heteroaryl residues, in the ring of which there is optionally one or more substituents, which are independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro and ester residues, and n is 0 or 1;
(viii) an amide of formula -NNSOH 10, wherein X 10 is selected from the group consisting of alkyl, hydroxyl, and five- or six-membered aryl or heteroaryl radicals, there are one or more substituents in the ring which optionally is independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylic acid, nitro or ester residues;
(ix) -SO 2 NX 11 X 12 , where X 11 and X 12 are independently selected from the group consisting of hydrogen, alkyl, and five- or six-membered aryl or heteroaryl residues;
(x) a five- or six-membered aryl or heteroaryl residue optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro and ester residues;
(xi) an aldehyde of the formula —CO — H; and
(xii) a sulfone of the formula —SO 2 —X 13 , wherein X 13 is selected from the group consisting of saturated or unsaturated alkyl and five- or six-membered aryl or heteroaryl residues; and
(b) X 1 is selected from the group consisting of nitrogen, sulfur and oxygen.
где (a) R1, R2, R3, R4 и R6 независимо выбирают из группы, включающей (i) водород; (ii) насыщенный или ненасыщенный алкил, замещенный по выбору пяти- или шестичленным арильным или гетероарильным остатками, в которых кольцо по выбору замещено одним, двумя или тремя заместителями, независимо выбранными из группы, включающей алкил, галоген, тригалогенметил, карбоксилат, нитро и сложноэфирные остатки; (iii) амин формулы NX2X3, где Х2 и Х3 независимо выбирают из группы, включающей водород, насыщенный или ненасыщенный алкил и пяти- или шестичленные арильные или гетероарильные остатки; (iv) галоген или тригалогенметил; (v) кетон формулы -СО-Х4, где Х4 выбирают из группы, включающей водород, алкил и пяти- или шестичленные арильные или гетероарильные остатки; (vi) карбоновая кислота формулы -(X5)n-COOH или сложный эфир формулы -(X6)n-COO-X7, где X5, X6 и Х7 независимо выбирают из группы, включающей алкил и пяти- или шестичленные арильные или гетероарильные остатки, а n равно 0 или 1; (vii) спирт формулы (X8)n-OH или алкоксиостаток формулы -(X8)n-O-Х9, где X8 и Х9 независимо выбирают из группы, включающей водород, насыщенный или ненасыщенный алкил и пяти- или шестичленные арильные или гетероарильные остатки, в кольце которых по выбору имеется один или более заместителей, которые независимо выбирают из группы, включающей алкил, галоген, тригалогенметил, карбоксилат, нитро и сложноэфирные остатки, а n равно 0 или 1; (viii) амид формулы -NНСОХ10, где Х10 выбирают из группы, включающей алкил, гидроксил и пяти- или шестичленные арильные или гетероарильные остатки, в кольце которых по выбору имеется один или более заместителей, которые независимо выбирают из группы, включающей алкил, галоген, тригалогенметил, карбокислат, нитро или сложноэфирные остатки; (ix) -SO2NX11X12, где Х11 и Х12 независимо выбирают из группы, включающей водород, алкил и пяти- или шестичленные арильные или гетероарильные остатки; (х) пяти- или шестичленный арильный или гетероарильный остаток, по выбору замещенный одним, двумя или тремя заместителями, независимо выбранными из группы, включающей алкил, галоген, тригалогенметил, карбоксилат, нитро и сложноэфирные остатки; (xi) альдегид формулы -СО-Н и (xii) сульфон формулы -SО2-Х13, где Х13 выбирают из группы, включающей насыщенный или ненасыщенный алкил и пяти- или шестичленные арильные или гетероарильные остатки; и (б) Х1 выбирают из группы, включающей азот, серу и кислород.16. A method for the prevention or treatment of a pathological condition of an organism, characterized in that compounds based on 5-azachinoxaline of the formula I are administered
where (a) R 1 , R 2 , R 3 , R 4 and R 6 are independently selected from the group consisting of (i) hydrogen; (ii) saturated or unsaturated alkyl optionally substituted with five- or six-membered aryl or heteroaryl residues in which the ring is optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, halogen, trihalogenomethyl, carboxylate, nitro and ester residues; (iii) an amine of the formula NX 2 X 3 , where X 2 and X 3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five- or six-membered aryl or heteroaryl residues; (iv) halogen or trihalogenomethyl; (v) a ketone of the formula —CO — X 4 , wherein X 4 is selected from the group consisting of hydrogen, alkyl, and five- or six-membered aryl or heteroaryl residues; (vi) a carboxylic acid of the formula - (X 5 ) n -COOH or an ester of the formula - (X 6 ) n -COO-X 7 , where X 5 , X 6 and X 7 are independently selected from the group consisting of alkyl and five- or six-membered aryl or heteroaryl residues, and n is 0 or 1; (vii) an alcohol of the formula (X 8 ) n- OH or an alkoxy radical of the formula - (X 8 ) n -O-X 9 , where X 8 and X 9 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five- or six-membered aryl or heteroaryl residues, in the ring of which there is optionally one or more substituents, which are independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro and ester residues, and n is 0 or 1; (viii) an amide of the formula —NHOX 10 , where X 10 is selected from the group consisting of alkyl, hydroxyl and five- or six-membered aryl or heteroaryl radicals, in the ring of which there are optionally one or more substituents which are independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylic acid, nitro or ester residues; (ix) -SO 2 NX 11 X 12 , where X 11 and X 12 are independently selected from the group consisting of hydrogen, alkyl, and five- or six-membered aryl or heteroaryl residues; (x) a five- or six-membered aryl or heteroaryl residue optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro and ester residues; (xi) an aldehyde of the formula —CO — H; and (xii) a sulfone of the formula —CO 2 —X 13 , wherein X 13 is selected from the group consisting of saturated or unsaturated alkyl and five- or six-membered aryl or heteroaryl residues; and (b) X 1 is selected from the group consisting of nitrogen, sulfur, and oxygen.
где (a) R1, R2, R3, R4 и R6 независимо выбирают из группы, включающей (i) водород; (ii) насыщенный или ненасыщенный алкил, замещенный по выбору пяти- или шестичленным арильным или гетероарильным остатками, в которых кольцо по выбору замещено одним, двумя или тремя заместителями, независимо выбранными из группы, включающей алкил, галоген, тригалогенметил, карбоксилат, нитро и сложноэфирные остатки; (iii) амин формулы NX2X3, где X2 и Х3 независимо выбирают из группы, включающей водород, насыщенный или ненасыщенный алкил и пяти- или шестичленные арильные или гетероарильные остатки; (iv) галоген или тригалогенметил; (v) кетон формулы -СО-Х4, где Х4 выбирают из группы, включающей водород, алкил и пяти- или шестичленные арильные или гетероарильные остатки; (vi) карбоновая кислота формулы -(X5)n-COOH или сложный эфир формулы -(X6)n-COO-X7, где Х5, X6 и Х7 независимо выбирают из группы, включающей алкил и пяти- или шестичленные арильные или гетероарильные остатки, а n равно 0 или 1; (vii) спирт формулы (X8)n-OH или алкоксиостаток формулы -(X8)n-O-Х9, где X8 и X9 независимо выбирают из группы, включающей водород, насыщенный или ненасыщенный алкил и пяти- или шестичленные арильные или гетероарильные остатки, в кольце которых по выбору имеется один или более заместителей, которые независимо выбирают из группы, включающей алкил, галоген, тригалогенметил, карбоксилат, нитро и сложноэфирные остатки, а n равно 0 или 1; (viii) амид формулы -NHCOX10, где Х10 выбирают из группы, включающей алкил, гидроксил и пяти- или шестичленные арильные или гетероарильные остатки, в кольце которых по выбору имеется один или более заместителей, которые независимо выбирают из группы, включающей алкил, галоген, тригалогенметил, карбокислат, нитро или сложноэфирные остатки; (ix) -SO2NX11X12, где Х11 и X12 независимо выбирают из группы, включающей водород, алкил и пяти- или шестичленные арильные или гетероарильные остатки; (х) пяти- или шестичленный арильный или гетероарильный остаток, по выбору замещенный одним, двумя или тремя заместителями, независимо выбранными из группы, включающей алкил, галоген, тригалогенметил, карбоксилат, нитро и сложноэфирные остатки; (xi) альдегид формулы -СО-Н и (xii) сульфон формулы -SO2-X13, где Х13 выбирают из группы, включающей насыщенный или ненасыщенный алкил и пяти- или шестичленные арильные или гетероарильные остатки; и (б) X1 выбирают из группы, включающей азот, серу и кислород.27. A compound based on 5-azachinoxaline having the structure represented by formula I
where (a) R 1 , R 2 , R 3 , R 4 and R 6 are independently selected from the group consisting of (i) hydrogen; (ii) saturated or unsaturated alkyl optionally substituted with five- or six-membered aryl or heteroaryl residues in which the ring is optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, halogen, trihalogenomethyl, carboxylate, nitro and ester residues; (iii) an amine of the formula NX 2 X 3 , where X 2 and X 3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five- or six-membered aryl or heteroaryl residues; (iv) halogen or trihalogenomethyl; (v) a ketone of the formula —CO — X 4 , wherein X 4 is selected from the group consisting of hydrogen, alkyl, and five- or six-membered aryl or heteroaryl residues; (vi) a carboxylic acid of the formula - (X 5 ) n -COOH or an ester of the formula - (X 6 ) n -COO-X 7 , where X 5 , X 6 and X 7 are independently selected from the group consisting of alkyl and five- or six-membered aryl or heteroaryl residues, and n is 0 or 1; (vii) an alcohol of the formula (X 8 ) n- OH or an alkoxy radical of the formula - (X 8 ) n -O-X 9 , where X 8 and X 9 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five- or six-membered aryl or heteroaryl residues, in the ring of which there is optionally one or more substituents, which are independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro and ester residues, and n is 0 or 1; (viii) an amide of the formula —NHCOX 10 , wherein X 10 is selected from the group consisting of alkyl, hydroxyl and five- or six-membered aryl or heteroaryl radicals, in the ring of which there are optionally one or more substituents which are independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylic acid, nitro or ester residues; (ix) —SO 2 NX 11 X 12 , wherein X 11 and X 12 are independently selected from the group consisting of hydrogen, alkyl, and five- or six-membered aryl or heteroaryl residues; (x) a five- or six-membered aryl or heteroaryl residue optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro and ester residues; (xi) an aldehyde of the formula —CO — H; and (xii) a sulfone of the formula —SO 2 —X 13 , wherein X 13 is selected from the group consisting of saturated or unsaturated alkyl and five- or six-membered aryl or heteroaryl residues; and (b) X 1 is selected from the group consisting of nitrogen, sulfur, and oxygen.
(iii) пяти- или шестичленные арильные или гетероарильные остатки, замещенные по выбору одним, двумя или тремя заместителями, независимо выбранными из группы, включающей алкил, галоген, тригалогенметил, гидрокси, алкокси, нитро и сложноэфирные остатки.28. The compound of claim 27, wherein said R 1 , R 2 , R 3 , R 4, and R 6 are independently selected from the group consisting of (i) hydrogen; (ii) saturated or unsaturated alkyl optionally substituted with five- or six-membered aryl or heteroaryl residues in which the ring is optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, hydroxy, alkoxy, carboxylate nitro and ester residues;
(iii) five- or six-membered aryl or heteroaryl residues optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, hydroxy, alkoxy, nitro and ester residues.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6112397P | 1997-10-06 | 1997-10-06 | |
US60/061,123 | 1997-10-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000111434A true RU2000111434A (en) | 2002-02-27 |
RU2223753C2 RU2223753C2 (en) | 2004-02-20 |
Family
ID=22033733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000111434/15A RU2223753C2 (en) | 1997-10-06 | 1998-10-05 | Methods for modulation of function of serine/threonine-protein kinase with 5-azaquinoxaline-base compounds, method for identification of compounds modulating function of serine/threonine-protein kinase, method for prophylaxis or treatment of body pathological state, 5-azaquinoxaline-base pharmaceutical composition and method for its synthesis |
Country Status (31)
Country | Link |
---|---|
US (2) | US6180631B1 (en) |
EP (1) | EP1028729B1 (en) |
JP (1) | JP2001518496A (en) |
KR (1) | KR100633270B1 (en) |
CN (1) | CN1169527C (en) |
AR (1) | AR013542A1 (en) |
AT (1) | ATE336250T1 (en) |
AU (1) | AU757585B2 (en) |
BG (1) | BG64969B1 (en) |
BR (1) | BR9814814A (en) |
CA (1) | CA2306257C (en) |
CY (1) | CY1106223T1 (en) |
CZ (1) | CZ298775B6 (en) |
DE (1) | DE69835612T2 (en) |
DK (1) | DK1028729T3 (en) |
ES (1) | ES2268791T3 (en) |
HK (1) | HK1031836A1 (en) |
HU (1) | HUP0100302A3 (en) |
IL (2) | IL135103A0 (en) |
MX (1) | MXPA03011007A (en) |
NO (1) | NO316598B1 (en) |
NZ (1) | NZ503431A (en) |
PL (1) | PL192039B1 (en) |
PT (1) | PT1028729E (en) |
RU (1) | RU2223753C2 (en) |
SK (1) | SK4722000A3 (en) |
TR (2) | TR200000906T2 (en) |
TW (1) | TWI245765B (en) |
UA (1) | UA71555C2 (en) |
WO (1) | WO1999017759A2 (en) |
ZA (1) | ZA988961B (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
JP2002534468A (en) * | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | ω-Carboxyaryl-substituted diphenylureas as p38 kinase inhibitors |
US8124630B2 (en) * | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
AU1053501A (en) * | 1999-11-02 | 2001-05-14 | Ajinomoto Co., Inc. | Polyazanaphthalene compound and medicinal use thereof |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
EP2324825A1 (en) * | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
US20040131504A1 (en) * | 2002-09-17 | 2004-07-08 | Landers James P. | Remote temperature sensing of small volume and related apparatus thereof |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
ATE366108T1 (en) * | 2003-05-20 | 2007-07-15 | Bayer Pharmaceuticals Corp | DIARYL UREAS FOR PDGFR-MEDIATED DISEASES |
BRPI0410633A (en) * | 2003-05-23 | 2006-06-13 | Zentaris Gmbh | pyridopyrazines and their use as kinase modulators |
DE102004022383A1 (en) * | 2004-05-06 | 2005-12-01 | Zentaris Gmbh | New pyridopyrazine derivatives are modulators of kinase activity, useful for the treatment of diseases associated with abnormal cellular signaling, e.g. tumors |
DE10323345A1 (en) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | New pyridopyrazines and their use as kinase inhibitors |
CA2529090A1 (en) * | 2003-06-13 | 2004-12-23 | Novartis Ag | 2-aminopyrimidine derivatives as raf kinase inhibitors |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
EP1790342A1 (en) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazine derivatives and their use as signal transduction modulators |
KR101400905B1 (en) * | 2005-11-11 | 2014-05-29 | 아에테르나 젠타리스 게엠베하 | Novel pyridopyrazines and their use as modulators of kinases |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
WO2010003308A1 (en) * | 2008-07-10 | 2010-01-14 | 卞化石 | The use of nitric oxide and signal transduction system thereof in preparing medicaments for targeted therapy of malignant tumors |
GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
EP2508184A1 (en) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazine derivatives and their use |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
CN104903320B (en) * | 2013-01-11 | 2018-11-13 | 富士胶片株式会社 | Nitrogen-containing heterocycle compound or its salt |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
DE102013008118A1 (en) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
JP6980385B2 (en) | 2014-03-26 | 2021-12-15 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | Combination of FGFR inhibitor and IGF1R inhibitor |
HUE053654T2 (en) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
DK3174868T3 (en) | 2014-08-01 | 2021-11-08 | Nuevolution As | COMPOUNDS ACTIVE AGAINST BROMODOMAINS |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
KR20180052631A (en) | 2015-09-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | Non-heteroaryl substituted 1,4-benzodiazepines and their use for the treatment of cancer |
BR112018005637B1 (en) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | COMPOUNDS DERIVED FROM QUINOXALINE, QUINOLINE AND QUINAZOLINONE, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND USE OF SAID COMPOUNDS |
US20190256492A1 (en) * | 2018-02-19 | 2019-08-22 | Washington University | Alpha-synuclein ligands |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4001017A (en) * | 1972-12-05 | 1977-01-04 | Ciba-Geigy Ag | Process for the photopolymerization of ethylenically unsaturated compounds |
US4043819A (en) * | 1974-06-11 | 1977-08-23 | Ciba-Geigy Ag | Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix |
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE3804990A1 (en) * | 1988-02-18 | 1989-08-31 | Basf Ag | HERBICIDALLY EFFECTIVE, HETEROCYCLICALLY SUBSTITUTED SULFONAMIDES |
FR2656606B1 (en) * | 1989-12-28 | 1993-06-25 | Roussel Uclaf | USE OF 9,10-DIHYDROPHENANTHRENE DERIVATIVES FOR THE PREPARATION OF AN ANTI-TUMOR DRUG, APPLICATION AS 9,10-DIHYDROPHENANTHRENE DERIVATIVES AND PRODUCTS DERIVED FROM THIS STRUCTURE. |
CA2078214C (en) | 1990-04-02 | 1995-03-28 | Robert Lee Dow | Benzylphosphonic acid tyrosine kinase inhibitors |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
DK0584222T3 (en) | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono and bicyclic aryl and heteroaryl compounds that inhibit EGF and / or PDGF receptor tyrosine kinase |
CA2108889A1 (en) | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
RU2155187C2 (en) | 1992-08-06 | 2000-08-27 | Варнер-Ламберт Компани | Derivatives of indole, their tautomers, mixtures of their isomers or separate isomers and pharmaceutically acceptable salts, pharmaceutical composition showing antitumor or inhibiting protein tyrosine kinase activity and method of inhibition of protein tyrosine kinase-depending disease or control of aberrant growth of mammalian or human cells |
US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5723462A (en) * | 1996-04-26 | 1998-03-03 | Neurogen Corporation | Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands |
UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
GB9726851D0 (en) * | 1997-12-19 | 1998-02-18 | Zeneca Ltd | Human signal transduction serine/threonine kinase |
-
1998
- 1998-05-10 UA UA2000052578A patent/UA71555C2/en unknown
- 1998-10-01 ZA ZA9808961A patent/ZA988961B/en unknown
- 1998-10-05 MX MXPA03011007A patent/MXPA03011007A/en not_active IP Right Cessation
- 1998-10-05 US US09/166,723 patent/US6180631B1/en not_active Expired - Fee Related
- 1998-10-05 TR TR2000/00906T patent/TR200000906T2/en unknown
- 1998-10-05 CA CA002306257A patent/CA2306257C/en not_active Expired - Fee Related
- 1998-10-05 DK DK98948606T patent/DK1028729T3/en active
- 1998-10-05 AT AT98948606T patent/ATE336250T1/en not_active IP Right Cessation
- 1998-10-05 PL PL339860A patent/PL192039B1/en not_active IP Right Cessation
- 1998-10-05 NZ NZ503431A patent/NZ503431A/en unknown
- 1998-10-05 WO PCT/US1998/020910 patent/WO1999017759A2/en active IP Right Grant
- 1998-10-05 CN CNB988099403A patent/CN1169527C/en not_active Expired - Fee Related
- 1998-10-05 CZ CZ20001129A patent/CZ298775B6/en not_active IP Right Cessation
- 1998-10-05 HU HU0100302A patent/HUP0100302A3/en not_active Application Discontinuation
- 1998-10-05 IL IL13510398A patent/IL135103A0/en not_active IP Right Cessation
- 1998-10-05 DE DE69835612T patent/DE69835612T2/en not_active Expired - Fee Related
- 1998-10-05 BR BR9814814-1A patent/BR9814814A/en not_active Application Discontinuation
- 1998-10-05 ES ES98948606T patent/ES2268791T3/en not_active Expired - Lifetime
- 1998-10-05 PT PT98948606T patent/PT1028729E/en unknown
- 1998-10-05 KR KR1020007003656A patent/KR100633270B1/en not_active IP Right Cessation
- 1998-10-05 RU RU2000111434/15A patent/RU2223753C2/en not_active IP Right Cessation
- 1998-10-05 SK SK472-2000A patent/SK4722000A3/en unknown
- 1998-10-05 EP EP98948606A patent/EP1028729B1/en not_active Expired - Lifetime
- 1998-10-05 JP JP2000514630A patent/JP2001518496A/en not_active Withdrawn
- 1998-10-05 AU AU95141/98A patent/AU757585B2/en not_active Ceased
- 1998-10-05 TR TR2001/00385T patent/TR200100385T2/en unknown
- 1998-10-06 AR ARP980104970A patent/AR013542A1/en unknown
- 1998-10-06 TW TW087116559A patent/TWI245765B/en not_active IP Right Cessation
-
2000
- 2000-03-15 IL IL135103A patent/IL135103A/en unknown
- 2000-04-05 NO NO20001748A patent/NO316598B1/en unknown
- 2000-04-28 BG BG104392A patent/BG64969B1/en unknown
- 2000-10-16 US US09/688,199 patent/US6727252B1/en not_active Expired - Fee Related
-
2001
- 2001-04-10 HK HK01102529A patent/HK1031836A1/en not_active IP Right Cessation
-
2006
- 2006-10-30 CY CY20061101554T patent/CY1106223T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000111434A (en) | A method for modulating the function of serine / threonine protein-based compound 5-AZAHINOKSALINA, methods for identifying compounds that modulate the function of serine / threonine protein kinase A method for preventing or treating pathological conditions, the pharmaceutical composition, the compound based on a 5-AZAHINOKSALINA AND METHOD OF SYNTHESIS | |
RU2223753C2 (en) | Methods for modulation of function of serine/threonine-protein kinase with 5-azaquinoxaline-base compounds, method for identification of compounds modulating function of serine/threonine-protein kinase, method for prophylaxis or treatment of body pathological state, 5-azaquinoxaline-base pharmaceutical composition and method for its synthesis | |
RU2000110736A (en) | A method for modulating the function of serine / threonine protein-based compound AZABENZIMIDAZOLA, methods for identifying compounds that modulate the function of serine / threonine protein kinase method for preventing or treating a pathological condition IN THE BODY-based compound AZABENZIMIDAZOLA, its method of synthesis and pharmaceutical compositions | |
Mastalir et al. | Air stable iron (II) PNP pincer complexes as efficient catalysts for the selective alkylation of amines with alcohols | |
Koike et al. | A novel biomimetic Zinc (II)− fluorophore, dansylamidoethyl− pendant macrocyclic tetraamine 1, 4, 7, 10-tetraazacyclododecane (cyclen) | |
Shi et al. | Catalytic, Asymmetric Aza‐Baylis–Hillman Reaction of N‐Sulfonated Imines with Activated Olefins by Quinidine‐Derived Chiral Amines | |
Costas et al. | Dioxygen activation at mononuclear nonheme iron active sites: enzymes, models, and intermediates | |
Hilt et al. | An Efficient Cobalt (i) Catalyst System for the Selective 1, 4‐Hydrovinylation of 1, 3‐Dienes | |
JP2001518496A5 (en) | ||
Hamann et al. | Monooxygenation of an appended phenol in a model system of tyrosinase: implications on the enzymatic reaction mechanism | |
CA2139293A1 (en) | Electrochemical assay method and novel p-phenylenediamine compound | |
Ellison et al. | Reactivity of five-coordinate models for the thiolate-ligated Fe site of nitrile hydratase | |
Duan et al. | Organocatalytic Asymmetric Benzylation and Aldol‐Hemiacetalization of α, β‐Unsaturated Trifluoromethyl Ketones: Efficient Enantioselective Construction of 3, 4‐Dihydroisocoumarins | |
Jiao et al. | Enantioselective Strecker Reactions between Aldimines and Trimethylsilyl Cyanide Promoted by Chiral N, N′‐Dioxides | |
Ton et al. | Copper (II) Triflate Catalyzed Amination of 1, 3‐Dicarbonyl Compounds | |
Wen et al. | Asymmetric three‐component Strecker reactions catalyzed by trans‐4‐hydroxy‐L‐proline‐derived N, N′‐dioxides | |
Zhou et al. | Development of highly efficient platinum catalysts for hydroalkoxylation and hydroamination of unactivated alkenes | |
Choi et al. | Rhenium (I) polypyridine diamine complexes as intracellular phosphorogenic sensors: Synthesis, characterization, emissive behavior, biological properties, and nitric oxide sensing | |
Tanaka et al. | Can heteroarenes/arenes be hydrogenated over catalytic Pd/C under ambient conditions? | |
Chung et al. | Induced Self‐Assembly of Platinum (II) Alkynyl Complexes through Specific Interactions between Citrate and Guanidinium for Proof‐of‐Principle Detection of Citrate and an Assay of Citrate Lyase | |
Türker et al. | The (NHC) PdBr 2 (2-aminopyridine) complexes: synthesis, characterization, molecular docking study, and inhibitor effects on the human serum carbonic anhydrase and serum bovine xanthine oxidase | |
Kaloğlu et al. | Ruthenium (II)‐(Arene)‐N‐Heterocyclic Carbene Complexes: Efficient and Selective Catalysts for the N‐Alkylation of Aromatic Amines with Alcohols | |
Fernández et al. | Synthesis, X-ray studies, and catalytic allylic amination reactions with ruthenium (IV) allyl carbonate complexes | |
Scholtes et al. | Design and synthesis of a stereodynamic catalyst with reversal of selectivity by enantioselective self‐inhibition | |
Lin et al. | Use of noncanonical tyrosine analogues to probe control of radical intermediates during endoperoxide installation by verruculogen synthase (FtmOx1) |